Back to search
FDAFDA · Food and drugs·Recall number D-0579-2023

Heparin Sodium, 25,000 USP units per 250mL, (100 USP units per mL) in 5% Dextrose injection, 250 ml Excel Container, B. Braun Medical Inc. Bethlehem, PA 18018, USA; API from Spain NDC: 0264-9587-20,

Published May 24, 2023 · Recall initiated: May 9, 2023

Summary

FDA records drug Class II recall D-0579-2023, published May 24, 2023 and initiated May 9, 2023. Recalling firm: B. Braun Medical Inc; Status: Terminated; Reported quantity: 1,380; Lot: Lot Number: J1P154N, Exp: 31 May, 2023,. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent: Low anti-factor IIa Potency.

What to do

Voluntary: Firm initiated · Letter

Get an email if HEPARIN SODIUM IN DEXTROSE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
HEPARIN SODIUM IN DEXTROSE
Manufacturer
B. Braun Medical Inc
Distributor
Nationwide in the USA
Lot
Lot Number: J1P154N, Exp: 31 May, 2023,
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Heparin Sodium, 25,000 USP units per 250mL, (100 USP units per mL) in 5% Dextrose injection, 250 ml Excel Container, B. Braun Medical Inc. Bethlehem, PA 18018, USA; API from Spain NDC: 0264-9587-20, recalled?

Yes. FDA published recall D-0579-2023 on May 24, 2023. Reported hazard: Subpotent: Low anti-factor IIa Potency.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: HEPARIN SODIUM IN DEXTROSE.